Kallidinogenase (DB13197): A Comprehensive Monograph on its Pharmacology, Clinical Application, and Global Status

Executive Summary

Kallidinogenase (DrugBank ID: DB13197) is a therapeutic enzyme belonging to the tissue kallikrein family of serine proteases. As a key component of the kallikrein-kinin system (KKS), its primary mechanism of action involves the enzymatic cleavage of kininogen to release potent vasoactive peptides, principally bradykinin and kallidin. This action initiates a cascade of multifaceted pharmacodynamic effects, including profound vasodilation, improvement of microcirculation, inhibition of platelet aggregation, and fibrinolysis. Beyond these hemodynamic actions, Kallidinogenase exerts significant neuroprotective, anti-inflammatory, anti-apoptotic, and pro-angiogenic effects, positioning it as a pleiotropic agent for the treatment of ischemic conditions.

The most robust clinical evidence for Kallidinogenase supports its use in the treatment of acute ischemic stroke (AIS). It is approved and recommended in clinical guidelines in China for this indication, where large-scale clinical trials have demonstrated its ability to improve neurological function and long-term functional outcomes. Its efficacy in AIS is attributed to a synergistic combination of acute improvement in cerebral perfusion and sub-acute to chronic modulation of inflammatory and regenerative processes. Other approved indications in certain Asian markets include peripheral circulatory disorders, diabetic complications, and menopausal disorders.

The safety profile of Kallidinogenase is well-characterized and directly predictable from its mechanism of action. The most common adverse events include transient hypotension and allergic reactions. A critical and pharmacologically certain drug interaction exists with Angiotensin-Converting Enzyme (ACE) inhibitors, which block bradykinin degradation; concurrent use is contraindicated due to the risk of severe hypotension.

A significant feature of Kallidinogenase is the pronounced divergence in its global regulatory status. While it is an established therapy in China, Japan, and South Korea, it remains unapproved by major Western regulatory bodies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Australian Therapeutic Goods Administration (TGA). This schism reflects a geographically concentrated evidence base, historical reliance on manufacturing processes involving extraction from animal or human sources, and differing regulatory standards. Future development and global acceptance will likely depend on the generation of data from large-scale, multicenter randomized controlled trials that meet global standards and the potential transition to standardized, high-purity recombinant production methods.

Drug Identity and Physicochemical Characteristics

This section establishes the fundamental scientific and pharmaceutical profile of Kallidinogenase, providing the foundational knowledge required to understand its pharmacological and clinical properties.

Nomenclature and Identifiers

Kallidinogenase is identified by a consistent set of international scientific and regulatory codes, though it is also known by several synonyms that reflect its enzymatic function and historical context.

• Generic Name: Kallidinogenase [1]
• English Name: Kallidinogenase [User Query]
• Synonyms: Common synonyms include Kallikrein, Kalirechin, Kininogenase, and Kininogenin.[2] Due to its source and function, it is also referred to as Pancreatic Kininogenase or, more broadly, as a form of tissue kallikrein.[4]
• DrugBank ID: DB13197 [7]
• CAS Number: 9001-01-8 [1]
• EC Number: 232-574-5 [3]
• Unique Ingredient Identifier (UNII): OT9M1PSK9N [7]

Chemical and Biological Nature

Kallidinogenase is a complex biological product, defined by its enzymatic activity, protein structure, and biological origin.

• Drug Type: It is classified as a biotech or biological drug, specifically a therapeutic enzyme.[7]
• Biochemical Classification: Kallidinogenase is a glycoprotein belonging to the serine endopeptidase (protease) family.[9] Specifically, it is a form of tissue kallikrein (EC 3.4.21.35).[4] One characterization describes it as being composed of 18 amino acids and 4 different sugars, with an approximate molecular weight of 26,800 Daltons.[5]
• Biological Source: The therapeutic product is derived from various mammalian sources. The most frequently cited sources for commercial production are porcine pancreas and human urine.[1] Preparations derived from human urine are specifically termed Human Urinary Kallidinogenase (HUK).[11] Additionally, recombinant production methods using molecular biological techniques in host cells are under development as an alternative to extraction from natural sources.[14]

Physical Properties, Stability, and Formulation

The physical characteristics and formulation of Kallidinogenase are tailored to its intended route of administration and are critical for maintaining its enzymatic activity.

• Appearance: It is typically a white to off-white, or in some preparations, a light brown lyophilized powder.[1]
• Odor: The substance is either odorless or possesses a faint, characteristic odor.[1]
• Solubility: Kallidinogenase is freely soluble in water and normal saline, forming a colorless or yellowish clear solution. It is practically insoluble in organic solvents such as ethanol and diethyl ether.[1]
• Stability: The enzyme exhibits stability under weakly acidic or neutral conditions, with an optimal pH range of approximately 5.5 to 7.5.[1] It is labile and loses activity at high temperatures or in the presence of strong acids, strong bases, and oxidizing agents. As is common with enzymes, preparations with higher purity tend to be less stable.[5]
• Pharmaceutical Formulations: The drug is available in two primary formulations: enteric-coated tablets for oral administration and a sterile powder for reconstitution for injection (typically intravenous infusion or intramuscular injection).[1]
• Excipients and Stabilizers: To protect the enzyme's activity, particularly in oral formulations, specific excipients are used. Stabilizers such as sodium alginate or inorganic salts (e.g., sodium carbonate, calcium chloride) are incorporated into the tablet core to prevent the loss of enzymatic titer during the manufacturing process. Other common adjuvants include fillers like starch and lactose, disintegrants such as carboxymethylstarch sodium, and binders like hypromellose.[15]

The source material and intended route of administration are not merely manufacturing details but are critical determinants of the final drug product's quality, potency, and clinical application. This is evident in the distinct pharmacopoeia standards that apply to different forms of the drug. For instance, Kallidinogenase derived from porcine pancreas is subject to different purity and activity specifications depending on whether it is formulated for oral or injectable use.[1] The oral grade, compliant with the Chinese Pharmacopoeia (CP), requires a purity of ≥75% and a specific activity of ≥300 IU/mg protein. In contrast, the injectable grade, compliant with the Japanese Pharmacopoeia (JP), demands a higher purity of ≥90% and a specific activity of ≥600 IU/mg protein.[1] This stringent requirement for the parenteral form reflects the elevated safety and purity standards necessary for drugs administered directly into the bloodstream. Furthermore, the use of different biological sources, such as human urine for HUK, introduces another layer of complexity, necessitating specific manufacturing controls for viral safety, analogous to those required for animal-derived products.[1] Therefore, a nuanced understanding of Kallidinogenase requires recognition that the term encompasses a class of products whose clinical profiles are fundamentally shaped by their origin and pharmaceutical formulation.

Comprehensive Pharmacological Profile

Kallidinogenase exerts its therapeutic effects by modulating the kallikrein-kinin system (KKS), a critical endogenous pathway involved in regulating hemodynamics, inflammation, and tissue repair. Its mechanism of action is multifaceted, leading to a cascade of physiological responses that are beneficial in ischemic and inflammatory conditions.

The Kallikrein-Kinin System: A Central Role

The KKS is a complex network of proteins and peptides that plays a crucial role in regulating blood pressure, coagulation, pain, and inflammation.[10] Kallidinogenase is a central enzymatic component of this system. In vivo, it exists as an inactive zymogen, prekallikrein, which is converted to its active form by other proteases, such as trypsin.[1] There are two principal forms of kallikrein: plasma kallikrein (KLKB1) and tissue kallikrein (KLK1), which are transcribed from distinct genes.[4] The therapeutic agent Kallidinogenase is a form of tissue kallikrein, which is widely distributed in organs such as the pancreas, kidneys, and blood vessels.[4]

Primary Mechanism of Action

As a serine protease, the fundamental biochemical function of Kallidinogenase is the enzymatic cleavage of specific protein substrates known as kininogens. It acts on both high-molecular-weight kininogen (HMWK) and low-molecular-weight kininogen (LMWK) to release potent, short-lived vasoactive peptides called kinins.[1] The primary kinins generated are kallidin (also known as Lys-bradykinin) and bradykinin.[8] Kallidin can be further converted into bradykinin by the action of aminopeptidases, making bradykinin the principal effector molecule of the system.[19]

Pharmacodynamic Effects

The release of kinins, particularly bradykinin, initiates a broad spectrum of downstream pharmacodynamic effects that collectively contribute to the therapeutic efficacy of Kallidinogenase.

Hemodynamic and Vascular Effects

The most prominent effects of Kallidinogenase are on the vasculature and blood flow.

• Vasodilation: Bradykinin is a powerful vasodilator. It achieves this effect by binding to bradykinin B2 receptors located on the surface of endothelial cells. This receptor activation stimulates the synthesis and release of two key signaling molecules: nitric oxide (NO) and prostacyclin ().[8] Both NO and prostacyclin cause the relaxation of vascular smooth muscle, leading to the dilation of blood vessels, including arterioles and capillaries. This vasodilation reduces peripheral vascular resistance, improves overall blood flow, and can help regulate blood pressure.[1]
• Microcirculation Improvement: By selectively dilating arterioles, Kallidinogenase significantly enhances collateral circulation and improves microcirculation.[1] This action is particularly crucial in ischemic tissues, where it helps restore the balance between oxygen supply and demand, thereby protecting cells in the ischemic penumbra.[8]
• Increased Vascular Permeability: Kinins are known to increase the permeability of capillaries and post-capillary venules, a key feature of their role in inflammation and tissue repair.[1]

Thrombolytic and Anti-platelet Activity

Kallidinogenase also influences hemostasis and thrombosis through multiple mechanisms.

• Fibrinolysis: The enzyme acts as an activator of plasminogen, converting it into its active form, plasmin. Plasmin is the primary enzyme responsible for fibrinolysis, the process of breaking down fibrin clots. By promoting plasmin formation, Kallidinogenase facilitates the hydrolysis of insoluble fibrin into soluble degradation products, leading to thrombolysis.[1]
• Anti-platelet Effects: Kinins have been shown to inhibit the aggregation of platelets, which further contributes to the prevention of thrombus formation and propagation.[5]

Neuroprotective and Regenerative Properties

In the context of cerebral ischemia, Kallidinogenase demonstrates a range of effects that promote neuronal survival and tissue repair.

• Angiogenesis: A critical mechanism for long-term recovery from stroke is angiogenesis, the formation of new blood vessels. Kallidinogenase is a potent pro-angiogenic factor. This effect is mediated through the activation of both bradykinin B1 and B2 receptors. This receptor activation, in turn, enhances the expression of other key angiogenic factors, including Vascular Endothelial Growth Factor (VEGF) and the apelin/APJ signaling system. This entire cascade is dependent on the activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway, specifically ERK1/2.[11]
• Neurogenesis: Preclinical studies indicate that Kallidinogenase treatment enhances neurogenesis, stimulating the proliferation of neural progenitor cells in key regenerative zones of the brain, such as the subventricular zone and the peri-infarction cortex, following ischemic injury.[13]
• Anti-apoptotic Effects: Kinins possess direct anti-apoptotic properties, helping to prevent programmed cell death in tissues subjected to ischemia-reperfusion injury.[8]

Anti-inflammatory and Anti-oxidative Actions

Ischemic injury triggers a robust inflammatory and oxidative stress response, which contributes to secondary tissue damage. Kallidinogenase actively counteracts these processes.

• Anti-inflammation: The drug has been shown to suppress post-stroke inflammatory cascades.[20] Mechanistically, it inhibits the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, a master regulator of pro-inflammatory gene expression. Concurrently, it activates the protective MAPK/ERK pathway.[23]
• Anti-oxidation: Kallidinogenase also functions as an anti-oxidative agent, helping to mitigate the damaging effects of reactive oxygen species that are generated during and after an ischemic event.[13]

The therapeutic value of Kallidinogenase in conditions like acute ischemic stroke arises not from a single, isolated action but from a synergistic combination of these pleiotropic effects. The drug's activity can be understood as a multi-stage intervention. In the immediate aftermath of an ischemic event, its potent vasodilatory properties work to acutely restore cerebral blood flow and improve perfusion to the threatened penumbra.[8] This addresses the primary insult. Subsequently, as the secondary injury cascade unfolds over hours to days, the drug's anti-inflammatory, anti-apoptotic, and anti-oxidative actions come to the fore, protecting vulnerable neurons from further damage by modulating key signaling pathways like NF-κB.[21] Finally, in the sub-acute to chronic phase of recovery, which extends over days to weeks, its ability to promote angiogenesis and neurogenesis supports long-term tissue remodeling and functional recovery.[13] This comprehensive, time-dependent engagement with the pathophysiology of ischemic injury explains why Kallidinogenase demonstrates sustained benefits on neurological and functional outcomes long after the initial treatment course has ended, and distinguishes it from therapeutic agents that may possess only a single mode of action.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

Comprehensive pharmacokinetic data for Kallidinogenase are not extensively detailed in the available documentation. However, a functional profile of its absorption, distribution, metabolism, and excretion (ADME) can be constructed from information regarding its administration routes, biological nature, and mechanism of action.

Administration and Absorption

The route of administration is a critical determinant of Kallidinogenase's bioavailability and clinical utility.

• Routes of Administration: The drug is formulated for both oral administration, as enteric-coated tablets, and parenteral administration, via intravenous injection or infusion.[1]
• Absorption Profile:
• Parenteral (Intravenous): Administration by intravenous infusion bypasses the absorption phase entirely, resulting in 100% bioavailability. This route ensures a rapid onset of action, with pharmacodynamic effects such as improved blood flow being observed within minutes to a few hours post-administration. Consequently, this is the exclusive route used in the treatment of acute conditions like ischemic stroke, where immediate therapeutic effect is paramount.[8]
• Oral: As a glycoprotein, Kallidinogenase is susceptible to degradation by proteases in the gastrointestinal tract. Evidence suggests that its absorption after oral administration is low and may be inconsistent. A clinical trial investigating oral Kallidinogenase for the treatment of male infertility failed to show efficacy, with the investigators postulating that a "very low absorption rate" was the likely cause of the negative result.[27] The use of specialized enteric-coated tablet formulations is a pharmaceutical strategy specifically designed to mitigate this issue by protecting the enzyme from the acidic environment of the stomach and allowing for its release and potential absorption in the more neutral pH of the intestine.[15]

Distribution

Following systemic absorption or administration, Kallidinogenase is distributed via the circulatory system to its sites of action.

• As a relatively large protein, it is expected to be primarily confined to the vascular and interstitial compartments.
• Its documented therapeutic effects on a wide range of organs—including the brain, heart, kidneys, and retina—confirm that it is effectively distributed to these tissues via the bloodstream.[1]
• Endogenously, tissue kallikrein is known to be widely distributed in various tissues, including the kidneys, blood vessels, pancreas, and the central nervous system, which are also its therapeutic targets.[13]

Metabolism

The metabolism of Kallidinogenase is intrinsically linked to its enzymatic function and the fate of its products.

• The primary "metabolic" role of Kallidinogenase itself is the catalytic cleavage of its substrate, kininogen, to produce the active peptides kallidin and bradykinin.[19]
• The key metabolic event that terminates the drug's action is the rapid degradation of these effector molecules. Bradykinin and kallidin have extremely short biological half-lives, as they are swiftly inactivated by enzymes known as kininases. The most significant of these is Angiotensin-Converting Enzyme (ACE), which efficiently cleaves and inactivates bradykinin.[19] This rapid clearance ensures that the potent effects of kinins are localized and tightly regulated.

Excretion

The primary route of elimination for Kallidinogenase appears to be renal.

• The fact that a clinically active form of the enzyme, Human Urinary Kallidinogenase (HUK), is extracted directly from human urine provides strong evidence that the kidneys are a major pathway for its excretion.[8]
• Specific data regarding the elimination half-life or clearance rates are not available in the provided documentation.

The pronounced difference in bioavailability between the parenteral and oral routes is the most significant pharmacokinetic characteristic of Kallidinogenase, and it fundamentally dictates the drug's clinical strategy. The consistent success observed in clinical trials for acute ischemic stroke is invariably linked to the use of intravenous administration, which guarantees rapid and complete delivery of the active enzyme to the systemic circulation, a necessity for intervening in the acute ischemic cascade.[11] In stark contrast, the documented failure of an oral formulation in a trial for a chronic condition highlights the formidable challenge of achieving reliable gastrointestinal absorption for a protein-based therapeutic.[27] This pharmacokinetic limitation effectively bifurcates the drug's application: for acute, high-stakes indications like stroke, the intravenous route is the only viable option. For chronic conditions where the convenience of oral dosing is preferred, the development of a formulation that can consistently overcome the absorption barrier remains a significant and, as yet, unresolved pharmaceutical hurdle.

Clinical Evidence and Therapeutic Applications

The clinical utility of Kallidinogenase has been investigated across a range of conditions characterized by circulatory dysfunction and ischemia. The most substantial body of evidence supports its use in acute ischemic stroke, where it has become a standard therapy in some parts of the world.

Primary Indication: Acute Ischemic Stroke (AIS)

Kallidinogenase, particularly in the form of Human Urinary Kallidinogenase (HUK), has a well-established role in the management of AIS in certain regions.

• Regulatory Context: HUK has been approved by the State Food and Drug Administration of China since 2005 for the treatment of mild-to-moderate AIS.[26] It is incorporated into Chinese clinical guidelines, which recommend its use in AIS patients within 48 hours of symptom onset, a therapeutic window that is considerably longer than that for traditional thrombolytics.[30]
• Evidence from Clinical Trials: A robust body of clinical evidence supports its efficacy.
• Efficacy and Functional Outcomes: Multiple randomized controlled trials, pooled analyses of Phase IIb and III data, and large-scale, real-world Phase IV studies (such as the RESK study, which enrolled over 1200 patients) have consistently demonstrated that HUK treatment leads to significant improvements in both neurological and functional outcomes compared to placebo or baseline.[11]
• Clinical Endpoints: The primary measures of efficacy in these trials are standardized stroke scales. Treatment with HUK results in statistically significant reductions in the National Institutes of Health Stroke Scale (NIHSS) score, indicating an amelioration of neurological deficits, and a greater proportion of patients achieving favorable outcomes (e.g., a score of 0-2) on the modified Rankin Scale (mRS), signifying less long-term disability.[11]
• Physiological Impact: The clinical benefits are underpinned by measurable physiological changes. Studies utilizing advanced imaging techniques like perfusion magnetic resonance imaging (MRI) have confirmed that HUK administration enhances cerebral blood flow (CBF), improves overall cerebral perfusion in the ischemic penumbra, and shortens the mean transit time (MTT) of blood through the affected brain tissue.[20]
• Combination Therapy: HUK has shown promise as an adjunctive therapy. Studies investigating its use in combination with other neuroprotective agents, such as edaravone and butylphthalide, have reported synergistic effects, leading to better clinical outcomes than monotherapy.[21] Furthermore, several ongoing clinical trials are actively evaluating the efficacy and safety of adding HUK to the current standard of care for AIS, which includes reperfusion therapies like intravenous thrombolysis (e.g., rt-PA) and endovascular treatment (mechanical thrombectomy).[36]
• Ongoing Research: The clinical development of Kallidinogenase continues to evolve. Active, large-scale clinical trials are underway to further delineate its role in specific, high-risk AIS populations, including patients with large artery atherosclerotic stroke (NCT06137300) and those with comorbid type 2 diabetes mellitus (NCT06085378), a group known to have poorer stroke outcomes.[38]

Other Approved and Investigational Indications

Beyond AIS, Kallidinogenase is approved and used for a variety of other conditions, primarily in Asian markets.

• Peripheral Circulatory Disorders: In Japan and South Korea, it is an approved therapy for improving symptoms associated with peripheral circulatory disturbances. This includes conditions such as essential hypertension, thromboangiitis obliterans (Buerger's disease), and Meniere's syndrome.[40]
• Diabetic Complications: Clinical evidence suggests a therapeutic benefit in diabetic microvascular complications. It has been reported to be effective in preventing diabetic microangiopathy and in treating early-stage diabetic nephropathy, where it can reduce the rate of urinary albumin excretion.[1] A major randomized, double-blind, placebo-controlled trial is currently planned to formally evaluate its efficacy and safety in AIS patients who also have type 2 diabetes.[39]
• Retinal and Choroidal Disorders: It is indicated for the treatment of retinochoroidal circulation disorders.[16] This clinical use is supported by preclinical data showing that Kallidinogenase protects retinal ganglion cells from ischemia/reperfusion injury in animal models, an effect potentially mediated by the activation of endothelial nitric oxide synthase (eNOS).[6]
• Climacteric (Menopausal) Disorders: The improvement of various symptoms associated with menopause is a listed indication in some product monographs.[40]
• Male Infertility: Kallidinogenase has been investigated for its potential to treat some forms of male infertility, such as oligozoospermia, based on the hypothesis that it may increase sperm activity and quantity.[5] However, at least one clinical trial using an oral formulation failed to demonstrate a benefit over placebo.[27]

A critical analysis of the available evidence reveals that the clinical data supporting Kallidinogenase, especially for its primary indication of AIS, is overwhelmingly concentrated in studies conducted in China. The drug's approval and inclusion in national treatment guidelines are specific to China.[26] Major clinical trials, including the pivotal RESK study, were conducted exclusively in Chinese patient populations.[11] Meta-analyses assessing its efficacy often rely heavily on Chinese-language databases and publications.[26] This regional focus stands in stark contrast to the absence of regulatory approval or significant clinical trial activity in the United States, Europe, or Australia. This geographical concentration is a defining characteristic of the drug's development history and raises important questions regarding the global generalizability of the existing efficacy and safety data, potential ethnic differences in the KKS, and variations in the standard of care for stroke that could influence trial outcomes.

Table 1: Summary of Major Clinical Trials of Kallidinogenase in Acute Ischemic Stroke

Trial Identifier/Name	Phase	Study Design	Patient Population	Intervention	Key Efficacy Outcomes	Key Safety Findings	Source(s)
RESK Study (NCT02562183)	IV	Single-arm, multicenter	1202 patients with AIS of anterior circulation	HUK 0.15 PNA units IV daily for 21 days	Favorable neurological and functional outcomes from baseline to post-treatment assessment.	Acceptable safety and tolerability. Incidence of serious AEs was 2.41%. Drug-related blood pressure reduction was associated with hypertension, age, and treatment time.	11
Pooled Phase IIb/III Trials	IIb/III	Randomized, double-blind, placebo-controlled	AIS patients	HUK injection vs. placebo	Significant improvements in European Stroke Scale (ESS) and Activities of Daily Living (ADL) scores compared to placebo. Lower rate of disability.	HUK-related adverse events occurred at a low rate (1.73%).	30
Meta-analysis of 16 RCTs	N/A	Meta-analysis	1326 patients with AIS	HUK injection vs. control	Significant improvement in NIHSS scores (MD -1.65) and clinical efficacy (RR 1.30) for HUK groups.	No significant difference in adverse effects between HUK and control groups.	26
NCT04102956	IV	N/A (Completed)	AIS patients	Kallidinogenase	To evaluate improvement in short-term motor functional outcome.	N/A	29
NCT06137300	N/A	Prospective, randomized, open-label, blinded-endpoint	Patients with large artery atherosclerotic AIS	Urinary kallidinogenase 0.15 PNA daily for 7 days vs. standard medical therapy	Primary: Proportion of patients with mRS score 0-2 at 90 days.	N/A (Ongoing)	38
NCT06085378 (TK-SEEK)	N/A	Randomized, double-blind, placebo-controlled	630 patients with AIS and type 2 diabetes	Urinary kallidinogenase 0.15 PNA daily for 10 days vs. placebo	N/A (Ongoing)	N/A (Ongoing)	39

Safety, Tolerability, and Risk Management

The safety profile of Kallidinogenase is well-documented and is intrinsically linked to its pharmacological mechanism of action. While generally well-tolerated, its use requires an understanding of its potential adverse effects, contraindications, and drug interactions to ensure patient safety.

Adverse Event Profile

Large-scale clinical studies and meta-analyses have established that Kallidinogenase has an acceptable safety and tolerability profile.

• Overall Tolerability: In a pooled analysis of Phase IIb and III clinical trials, adverse events specifically attributed to Human Urinary Kallidinogenase (HUK) were infrequent, occurring in only 1.73% of treated patients.[30] The large, real-world RESK study concluded that HUK has an acceptable safety profile in AIS patients, with a serious adverse event rate of just 2.41%.[11] Meta-analyses have found no statistically significant difference in the overall incidence of adverse events between HUK-treated groups and control groups.[26]
• Common Adverse Events: The most frequently reported adverse reactions are direct extensions of the drug's vasodilatory and biological nature.
• Hypotension: A transient decrease in blood pressure is a known and common side effect, resulting directly from the vasodilatory action of bradykinin. This effect is typically mild and can be managed by slowing the infusion rate, but it necessitates blood pressure monitoring during administration.[8]
• Allergic/Hypersensitivity Reactions: As a protein-based therapeutic, Kallidinogenase can elicit immune responses. Common manifestations include skin rash, itching (pruritus), and hives (urticaria). Swelling at the injection site may also occur. While rare, severe systemic reactions such as anaphylaxis are a potential risk and require immediate medical attention.[8]
• Gastrointestinal Discomfort: Symptoms such as nausea, vomiting, abdominal pain, loss of appetite, and diarrhea have been reported. These are more commonly associated with oral formulations and can often be managed by taking the medication with food.[16]
• Other Reported Effects: Dizziness, headache, fatigue, and a sensation of warmth or hot flush have also been documented.[8]

Contraindications and Precautions

The use of Kallidinogenase is contraindicated in specific patient populations where its physiological effects could be detrimental.

• Known Hypersensitivity: A history of allergic reaction to Kallidinogenase or any of its formulation components is an absolute contraindication.[8]
• Hemorrhagic Conditions: Due to its potential to interfere with hemostasis through vasodilation, anti-platelet effects, and fibrinolysis, Kallidinogenase is strictly contraindicated in patients with active bleeding or a high risk of hemorrhage. This includes patients with hemorrhagic stroke (intracerebral or subarachnoid), a recent history of significant bleeding (e.g., gastrointestinal), or underlying bleeding diatheses such as coagulation disorders or severe thrombocytopenia.[8]
• Severe Organ Dysfunction: Caution is advised, and the drug may be contraindicated in patients with severe, uncompensated cardiac, hepatic, or renal dysfunction.[8]
• Pregnancy and Lactation: The safety of Kallidinogenase during pregnancy and breastfeeding has not been established, and its use in these populations is generally avoided.[41]

Clinically Significant Drug-Drug Interactions

The most significant drug interactions with Kallidinogenase are pharmacodynamic in nature and stem from its effects on the KKS.

• Angiotensin-Converting Enzyme (ACE) Inhibitors: This represents the most critical and well-understood drug interaction. ACE is the primary enzyme responsible for the degradation and inactivation of bradykinin. ACE inhibitors (e.g., captopril, enalapril, lisinopril) block this enzyme. Therefore, the concurrent administration of Kallidinogenase (which increases bradykinin production) and an ACE inhibitor (which prevents its breakdown) leads to a synergistic accumulation of bradykinin. This can result in an exaggerated and potentially severe hypotensive response. Consequently, the use of ACE inhibitors is a standard and crucial exclusion criterion in clinical trials of Kallidinogenase, and their co-administration is contraindicated or strongly discouraged in clinical practice.[8]
• Anticoagulants and Antiplatelet Agents: Co-administration with medications such as warfarin, heparin, aspirin, or clopidogrel may theoretically augment the risk of bleeding. This is due to the combined effects of inhibiting coagulation or platelet function with the vasodilatory and anti-aggregatory properties of Kallidinogenase. Patients on concurrent therapy should be monitored closely for signs of bleeding.[8]

Toxicity and Overdose

Specific data on Kallidinogenase toxicity from overdose are not provided in the available materials. However, based on its known pharmacology, the clinical manifestations of an overdose would be an extension of its therapeutic effects. The primary signs would likely be severe and persistent hypotension, reflex tachycardia, and symptoms related to excessive vasodilation, such as flushing and headache.[50] Management would be symptomatic and supportive, focusing on volume expansion with intravenous fluids and, if necessary, the use of vasopressor agents to restore hemodynamic stability.

The safety profile of Kallidinogenase is not a collection of unrelated phenomena but is rather a direct and logical consequence of its fundamental mechanism of action. The drug's primary function is to catalyze the generation of bradykinin.[8] Since bradykinin is one of the body's most potent endogenous vasodilators, it follows logically that the principal dose-limiting adverse effect of the drug would be excessive vasodilation, manifesting as hypotension.[8] Similarly, the most critical drug interaction can be deduced from the metabolic fate of bradykinin. The enzyme primarily responsible for bradykinin's inactivation is ACE.[19] Therefore, combining a drug that increases bradykinin synthesis (Kallidinogenase) with a class of drugs that inhibits its degradation (ACE inhibitors) will predictably lead to a synergistic accumulation of bradykinin and a profound pharmacodynamic interaction, resulting in severe hypotension.[8] This clear mechanistic linkage provides a rational and robust basis for risk management, allowing clinicians to anticipate, monitor for, and mitigate the key safety concerns associated with Kallidinogenase therapy.

Table 2: Clinically Relevant Drug-Drug Interactions and Management Recommendations

Interacting Drug/Class	Mechanism of Interaction	Potential Clinical Outcome	Clinical Management Recommendation	Source(s)
Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., captopril, enalapril)	Inhibition of bradykinin degradation by ACE, leading to synergistic accumulation of bradykinin.	Severe, exaggerated, and prolonged hypotension.	Contraindicated. Concurrent use should be avoided. A sufficient washout period for ACE inhibitors is required before initiating Kallidinogenase.	8
Anticoagulants (e.g., warfarin, heparin) and Antiplatelet Agents (e.g., aspirin, clopidogrel)	Additive effects on hemostasis. Kallidinogenase has vasodilatory and anti-platelet properties that may increase bleeding risk when combined with agents that inhibit coagulation or platelet function.	Increased risk of bleeding or hemorrhage.	Use with caution. Patients should be closely monitored for signs of bleeding (e.g., bruising, hematuria, melena).	8

Dosage, Administration, and Global Status

This section details the practical aspects of Kallidinogenase use, including established dosing regimens, key players in its manufacturing and supply, and its divergent regulatory status across major global markets.

Recommended Dosing Regimens

The dosage and administration route for Kallidinogenase are highly dependent on the clinical indication.

• Acute Ischemic Stroke (Parenteral): For the treatment of AIS, the standard dose of Human Urinary Kallidinogenase (HUK) is 0.15 PNA (peptide nucleic acids) units. This dose is administered once daily via intravenous infusion, typically dissolved in 100 ml of sodium chloride injection. The duration of treatment generally ranges from 7 to 21 consecutive days, depending on the clinical protocol and patient response.[22]
• Peripheral Circulatory and Other Disorders (Oral): For chronic conditions treated with oral enteric-coated tablets, the typical adult dosage is between 30 and 150 International Units (I.U.) per day. This total daily dose is usually divided and administered three times a day (e.g., 10 to 50 I.U. per dose). The specific dosage is adjusted by the prescribing physician according to the patient's age, symptoms, and the specific condition being treated.[16]

Manufacturing and Supply Chain

The production of Kallidinogenase relies on complex biological extraction processes or emerging recombinant technologies, with key manufacturers concentrated in Asia.

• Key Manufacturers: Sichuan Deebio Pharmaceutical Co., Ltd. is a major Chinese manufacturer of the Kallidinogenase active pharmaceutical ingredient (API), holding Chinese Good Manufacturing Practice (GMP) certification and a Drug Master File (DMF) for the product.[18] Other entities involved in the development and formulation of Kallidinogenase products include Guangdong Techpool Bio-pharma (producer of the Kailikang brand), Changchun Haiyue Pharmaceutical, and Jiangsu Aidea Pharmaceutical in China.[17] In Japan, Nichi-Iko Pharmaceutical is a prominent manufacturer of Kallidinogenase tablets.[55]
• Production Processes: Historically and currently, the primary method of production involves extraction from biological source materials. This includes the isolation of the enzyme from porcine pancreas or its purification from pooled human urine (for HUK).[1] These processes must adhere to strict GMP standards, which include validated steps for viral inactivation to ensure the safety of the final biological product.[1] In parallel, modern biotechnological approaches are being developed. These involve the use of recombinant DNA technology to express the human kallidinogenase gene in host cell systems, such as Chinese Hamster Ovary (CHO) cells, followed by purification. This recombinant approach offers the potential for a more standardized, consistent, and potentially safer source of the enzyme compared to extraction from natural sources.[14]

Regulatory Approvals and Brand Names

Kallidinogenase presents a clear case of regulatory divergence, being an established medicine in several major Asian countries while remaining unapproved in Western markets.

• China: HUK is approved as a state category I new drug for the treatment of acute ischemic stroke. A widely used brand name is Kailikang (produced by Guangdong Techpool Bio-pharma).[22] An approval number cited for a Kallidinogenase product from Sichuan Deebio is GUOYAOZHUNZI H19993782.[18]
• Japan: The drug is approved by the Pharmaceuticals and Medical Devices Agency (PMDA) for a range of indications, including the improvement of symptoms related to peripheral circulatory disorders (in hypertension, Meniere's disease, Buerger's disease), retinochoroidal circulatory disturbance, and climacteric disorders.[16] Commercially available brand names include Kallidinogenase Tablets "Nichiiko", Kallidinogenase Tablets "SAWAI", and CARNACULIN.[16]
• South Korea: It is available as a prescription medicine. A known brand name is Kanase Tab..[40]
• United States (FDA), Europe (EMA), and Australia (TGA): The provided documentation contains no evidence that Kallidinogenase has been submitted for review or granted marketing authorization for any indication by the FDA, EMA, or TGA. Searches of regulatory databases and guidance documents from these agencies do not yield any approval information for this drug, indicating it is not a legally marketed therapeutic in these major Western regions.[59]

The global landscape of Kallidinogenase illustrates a tale of two distinct regulatory worlds. In major Asian markets like China and Japan, it is an established, approved, and guideline-integrated therapy for significant medical conditions.[16] In contrast, in the West, it remains effectively an unapproved and largely investigational agent. This significant schism is not arbitrary but is likely the result of several interconnected factors. First, the clinical evidence base, while substantial, has been generated almost exclusively within Asian patient populations, which may raise questions of generalizability for Western regulatory bodies.[11] Second, the traditional manufacturing processes, which rely on extraction from animal tissues or human biological fluids, can face higher regulatory hurdles in the U.S. and E.U. concerning batch-to-batch consistency, purity, and viral safety compared to chemically synthesized small molecules or well-characterized recombinant proteins.[1] Finally, regulatory agencies in different regions may have varying standards for clinical trial design, data analysis, and the overall benefit-risk assessment. This divergence highlights the considerable challenges in globalizing a drug that has been developed and validated primarily within a single geographical and regulatory ecosystem.

Table 3: Global Regulatory Status and Commercial Availability of Kallidinogenase

Country/Region	Regulatory Agency	Approval Status	Approved/Investigated Indications	Known Brand Name(s)	Source(s)
China	National Medical Products Administration (NMPA)	Approved	Acute Ischemic Stroke (AIS)	Kailikang	22
Japan	Pharmaceuticals and Medical Devices Agency (PMDA)	Approved	Peripheral circulatory disorders, Meniere's syndrome, retinochoroidal circulatory disorders, climacteric disorders.	Kallidinogenase "Nichiiko", Kallidinogenase "SAWAI", CARNACULIN	16
South Korea	Ministry of Food and Drug Safety (MFDS)	Approved	Peripheral circulatory disorders, Meniere's syndrome, climacteric disorders.	Kanase Tab.	40
United States	Food and Drug Administration (FDA)	Not Approved	N/A	N/A	61
European Union	European Medicines Agency (EMA)	Not Approved	N/A	N/A	60
Australia	Therapeutic Goods Administration (TGA)	Not Approved	N/A	N/A	62

Synthesis and Future Perspectives

Kallidinogenase emerges from this comprehensive analysis as a therapeutic agent with a compelling, multifaceted mechanism of action and a significant, albeit geographically concentrated, role in modern pharmacotherapy. Its unique position as a modulator of the fundamental kallikrein-kinin system allows it to exert a pleiotropic combination of vasodilatory, anti-thrombotic, anti-inflammatory, and pro-regenerative effects. This makes it an exceptionally well-suited candidate for treating complex ischemic pathologies, most notably acute ischemic stroke.

The clinical evidence from Asia, particularly China, is substantial. Large-scale trials and real-world data support its efficacy in improving neurological and functional outcomes in AIS patients, leading to its integration into national treatment guidelines. This regional success, however, is contrasted by a notable absence from the therapeutic arsenals of Western medicine. This regulatory and clinical divergence is a defining feature of the drug's current status and is likely attributable to a confluence of factors: a clinical evidence base that has not yet been globalized, a reliance on traditional biological extraction manufacturing methods that may face higher scrutiny from agencies like the FDA and EMA, and potentially different standards for clinical evidence required for marketing authorization.

The future trajectory of Kallidinogenase on the global stage will depend on addressing these key challenges and pursuing several clear avenues of research and development.

1. Globalized Clinical Trials: The foremost requirement for broader acceptance is the execution of large-scale, multicenter, randomized, double-blind, placebo-controlled trials that are designed and conducted to meet the rigorous standards of the FDA, EMA, and other major international regulatory bodies. Such trials must enroll diverse patient populations to establish the generalizability of the efficacy and safety data observed in Asian cohorts.
2. Transition to Recombinant Production: The development and validation of high-purity, well-characterized recombinant human Kallidinogenase represents a critical step forward. A recombinant product would overcome many of the regulatory concerns associated with extraction from animal or human sources, ensuring greater batch-to-batch consistency, purity, and an enhanced safety profile. This would significantly streamline the path to regulatory review in Western markets.
3. Exploration of New Indications: The potent anti-ischemic and anti-inflammatory properties of Kallidinogenase suggest its potential utility extends beyond stroke. Rigorous clinical investigation is warranted in other diseases characterized by microvascular dysfunction and inflammation, such as chronic kidney disease, diabetic retinopathy, and certain forms of cardiovascular disease like coronary microvascular dysfunction.
4. Optimization of Combination Therapies: Early evidence suggests that Kallidinogenase may act synergistically with other neuroprotective and reperfusion therapies. Future clinical trials should be designed to systematically evaluate its role as an adjunctive agent to the current standards of care for AIS, including thrombolysis and mechanical thrombectomy, to determine if it can further improve outcomes in these patient populations.

In conclusion, Kallidinogenase is a valuable therapeutic enzyme with a proven record of efficacy and safety in specific clinical contexts and regions. Its future as a global therapeutic agent hinges on bridging the existing evidence and regulatory gaps through strategic clinical development and manufacturing innovation. If these hurdles can be overcome, Kallidinogenase has the potential to become a vital addition to the global armamentarium for treating ischemic and vascular diseases.

Works cited

1. Buy Kallidinogenase CAS No.: 9001-01-8 (kinin-releasing activity ..., accessed October 14, 2025, https://www.haoranbiopharma.com/kallidinogenase-cas-no-9001-01-8-kinin-releasing-activity-product/
2. CAS No : 9001-01-8 | Product Name : Kallidinogenase | Pharmaffiliates, accessed October 14, 2025, https://www.pharmaffiliates.com/en/9001-01-8-kallidinogenase-pa270026799.html
3. CAS 9001-01-8 - Sigma-Aldrich, accessed October 14, 2025, https://www.sigmaaldrich.com/US/en/search/9001-01-8?focus=products&page=1&perpage=30&sort=relevance&term=9001-01-8&type=cas_number
4. 9001-01-8 | CAS DataBase - ChemicalBook, accessed October 14, 2025, https://www.chemicalbook.com/CASEN_9001-01-8.htm
5. Pancreatic Kininogenase Or Kallidinogenase Manufacturers and Suppliers - Fengchen, accessed October 14, 2025, https://www.fengchengroup.com/enzymes-and-bio-products/enzymes/pancreatic-kininogenase-or-kallidinogenase.html
6. Tissue kallikrein (kallidinogenase) protects against retinal ischemic damage in mice - PubMed, accessed October 14, 2025, https://pubmed.ncbi.nlm.nih.gov/24877690/
7. Kallidinogenase API Suppliers - Find All GMP Manufacturers - Pharmaoffer.com, accessed October 14, 2025, https://pharmaoffer.com/api-excipient-supplier/other-substances/kallidinogenase
8. What is Urinary Kallidinogenase used for? - Patsnap Synapse, accessed October 14, 2025, https://synapse.patsnap.com/article/what-is-urinary-kallidinogenase-used-for
9. Kallikreins | DrugBank Online, accessed October 14, 2025, https://go.drugbank.com/categories/DBCAT004921
10. What is Kallidinogenase used for? - Patsnap Synapse, accessed October 14, 2025, https://synapse.patsnap.com/article/what-is-kallidinogenase-used-for
11. Human urinary kallidinogenase in acute ischemic stroke: A single‐arm, multicenter, phase IV study (RESK study) - ResearchGate, accessed October 14, 2025, https://www.researchgate.net/publication/354539081_Human_urinary_kallidinogenase_in_acute_ischemic_stroke_A_single-arm_multicenter_phase_IV_study_RESK_study
12. pmc.ncbi.nlm.nih.gov, accessed October 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7780570/#:~:text=Objective,of%20the%20kallikrein%E2%80%93kinin%20system.
13. Therapeutic Values of Human Urinary Kallidinogenase on ..., accessed October 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5996104/
14. CN101967468A - Recombinant human kallidinogenase - Google ..., accessed October 14, 2025, https://patents.google.com/patent/CN101967468A/en
15. CN102813637A - Kallidinogenase enteric coated tablet and preparation method thereof - Google Patents, accessed October 14, 2025, https://patents.google.com/patent/CN102813637A/en
16. KALLIDINOGENASE Tablets 50 Units "SAWAI" | Kusuri-no-Shiori ..., accessed October 14, 2025, https://www.rad-ar.or.jp/siori/english/search/result?n=47019
17. CN104069486A - Pharmaceutical composition containing kallidinogenase and preparation thereof - Google Patents, accessed October 14, 2025, https://patents.google.com/patent/CN104069486A/en
18. Sichuan Deebio Pharmaceutical, accessed October 14, 2025, https://en.deebio.com/?c=index&a=cate&classid=24
19. What is the mechanism of Kallidinogenase? - Patsnap Synapse, accessed October 14, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-kallidinogenase
20. Human Urinary Kallidinogenase Promotes Angiogenesis and ..., accessed October 14, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134543
21. Efficacy and Safety of Dl-3-n-Butylphthalide Combined With Human Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke - ResearchGate, accessed October 14, 2025, https://www.researchgate.net/publication/368569002_Efficacy_and_Safety_of_Dl-3-n-Butylphthalide_Combined_With_Human_Urinary_Kallidinogenase_in_the_Treatment_of_Acute_Ischemic_Stroke
22. Human Urinary Kallidinogenase decreases recurrence risk and ..., accessed October 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6085914/
23. (PDF) Unlocking the therapeutic potential of human urinary kallidinogenase in stroke: a mini review - ResearchGate, accessed October 14, 2025, https://www.researchgate.net/publication/391368758_Unlocking_the_therapeutic_potential_of_human_urinary_kallidinogenase_in_stroke_a_mini_review
24. Human urinary kallidinogenase suppresses cerebral inflammation in ..., accessed October 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2949229/
25. Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke | Neurosciences Journal, accessed October 14, 2025, https://nsj.org.sa/content/21/2/126
26. Efficacy and safety of human urinary kallidinogenase for acute ischemic stroke: a meta-analysis - PMC, accessed October 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7780570/
27. Efficacy of kallikrein in the treatment of oligozoospermia and asthenozoospermia: A double-blind trial - Tel Aviv University, accessed October 14, 2025, https://cris.tau.ac.il/en/publications/efficacy-of-kallikrein-in-the-treatment-of-oligozoospermia-and-as
28. Human urinary kallidinogenase decreases the incidence of post-stroke cognitive impairment in acute ischemic stroke patients - Semantic Scholar, accessed October 14, 2025, https://pdfs.semanticscholar.org/144f/77583a2ba871d33821af6bab5a79f6e023b3.pdf
29. Kallidinogenase Completed Phase 4 Trials for Stroke, Acute Treatment | DrugBank Online, accessed October 14, 2025, https://go.drugbank.com/drugs/DB13197/clinical_trials?conditions=DBCOND0030361&phase=4&purpose=treatment&status=completed
30. Human urinary kallidinogenase in treating acute ischemic stroke patients: analyses of pooled data from a randomized double-blind placebo-controlled phase IIb and phase III clinical trial - ResearchGate, accessed October 14, 2025, https://www.researchgate.net/publication/339499694_Human_urinary_kallidinogenase_in_treating_acute_ischemic_stroke_patients_analyses_of_pooled_data_from_a_randomized_double-blind_placebo-controlled_phase_IIb_and_phase_III_clinical_trial
31. Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients - PubMed, accessed October 14, 2025, https://pubmed.ncbi.nlm.nih.gov/28265861/
32. Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke - PMC, accessed October 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5107266/
33. Human Urinary Kallidinogenase Improves Outcome of Stroke ..., accessed October 14, 2025, https://pubmed.ncbi.nlm.nih.gov/26139453/
34. Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis-Bohrium, accessed October 14, 2025, https://www.bohrium.com/paper-details/human-urinary-kallidinogenase-combined-with-edaravone-in-treating-acute-ischemic-stroke-patients-a-meta-analysis/813222624116080641-7701
35. Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke - ResearchGate, accessed October 14, 2025, https://www.researchgate.net/publication/336719150_Human_urinary_kallidinogenase_or_edaravone_combined_with_butylphthalide_in_the_treatment_of_acute_ischemic_stroke
36. Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment | TrialScreen, accessed October 14, 2025, https://app.trialscreen.org/trials/efficacy-safety-human-urinary-kallidinogenase-acute-ischemic-stroke-patients-trial-nct06848894
37. Study Details | NCT06848894 | Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment | ClinicalTrials.gov, accessed October 14, 2025, https://clinicaltrials.gov/study/NCT06848894
38. Study Details | NCT06137300 | Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke | ClinicalTrials.gov, accessed October 14, 2025, https://clinicaltrials.gov/study/NCT06137300
39. Study Details | NCT06085378 | Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus | ClinicalTrials.gov, accessed October 14, 2025, https://clinicaltrials.gov/study/NCT06085378?cond=%22Ischemia%22&intr=%22Kallikreins%22&viewType=Table&rank=10
40. 경동제약, accessed October 14, 2025, https://kdpharma.co.kr/m/en/productInfo/productView.php?goPage=GoodDetail&cat_no=78&idx=360
41. Kallidinogenase Tablets 50 Units "Nichiiko" | Kusuri-no-Shiori(Drug Information Sheet), accessed October 14, 2025, https://www.rad-ar.or.jp/siori/english/search/result?n=33122
42. Human urinary kallidinogenase in treating acute ischemic stroke patients: analyses of pooled data from a randomized double-blind placebo-controlled phase IIb and phase III clinical trial - PubMed, accessed October 14, 2025, https://pubmed.ncbi.nlm.nih.gov/32138624/
43. Efficacy and safety of human urinary kallidinogenase for acute ischemic stroke: a meta-analysis - PubMed, accessed October 14, 2025, https://pubmed.ncbi.nlm.nih.gov/32954870/
44. Efficacy of Human Urinary Kallidinogenase in Real-world Patients, accessed October 14, 2025, https://www.semanticscholar.org/paper/c78255d8bd2288c6aae2229ee96d058dd62985dc
45. What are the side effects of Urinary Kallidinogenase?, accessed October 14, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-urinary-kallidinogenase
46. Original Article Clinical efficacy and safety of urinary kallindinogenase combined with butylphthalide in the treatment of progressive cerebral infarction, accessed October 14, 2025, https://e-century.us/files/ajtr/13/12/ajtr0138906.pdf
47. What are the side effects of Kallidinogenase? - Patsnap Synapse, accessed October 14, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-kallidinogenase
48. Efficacy and Safety of Human Urinary Kallidinogenase Combined ..., accessed October 14, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06211712/efficacy-and-safety-of-human-urinary-kallidinogenase-combined-with-endovascular-therapy-in-acute-ischemic-stroke-with-large-vessel-occlusion
49. Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction. - SciSpace, accessed October 14, 2025, https://scispace.com/pdf/study-on-the-effect-of-urinary-kallidinogenase-after-2ydjfnfg99.pdf
50. Toxicology - Drugs - Medbullets Step 2/3, accessed October 14, 2025, https://step2.medbullets.com/drugs/121613/toxicology
51. Clonidine toxicity - LITFL, accessed October 14, 2025, https://litfl.com/clonidine-toxicity/
52. Kallidinogenase API Manufacturers | Suppliers | Exporters ..., accessed October 14, 2025, https://www.pharmacompass.com/listed-active-pharmaceutical-ingredients/kallidinogenase
53. Company Profile of Sichuan Deebio Pharmaceutical Co., Ltd. - m.pharmasources.com, accessed October 14, 2025, https://m.pharmasources.com/company-profile/sichuan-deebio-pharmaceutical-co-ltd-userId-374.html
54. Kallidinogenase proenzyme - Jiangsu Aidea Pharmaceutical - AdisInsight - Springer, accessed October 14, 2025, https://adisinsight.springer.com/drugs/800071432
55. Kallidinogenase Tablets 25 NichiIko 100Tablets | Natural Pharmacy, accessed October 14, 2025, https://www.mimaki-family-japan.com/item/detail?item_prefix=TF&item_code=003040&item_branch=001
56. US3994782A - Methods for extracting and purifying kallidinogenase - Google Patents, accessed October 14, 2025, https://patents.google.com/patent/US3994782A/en
57. Kallidinogenase - ChemBK, accessed October 14, 2025, https://www.chembk.com/en/chem/Kallidinogenase
58. Kallidinogenase Tablets 50 Units "NIG" : Nichi-Iko Pharmaceutical Co., Ltd. Gifu Plant, accessed October 14, 2025, https://synapse.inc/medicine/22961/
59. CDER Nitrosamine Impurity Acceptable Intake Limits - FDA, accessed October 14, 2025, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits
60. Regulatory aspects of the development of drugs for metabolic bone diseases – FDA and EMA perspective - PMC - PubMed Central, accessed October 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6533422/
61. Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Book - FDA, accessed October 14, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
62. Australian Register of Therapeutic Goods (ARTG) | Therapeutic ..., accessed October 14, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
63. Drug Approvals and Databases - FDA, accessed October 14, 2025, https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
64. Search | European Medicines Agency (EMA) - Europa.eu, accessed October 14, 2025, https://www.ema.europa.eu/en/search